Common Contracts

1 similar Licensing and Supply Agreement contracts

Licensing and supply agreement for MR-proADM, MR-proANP, and CT-proET1
Licensing and Supply Agreement • June 20th, 2024

It will provide diaDexus with the ability to develop and commercialize three independent biomarkers (MR-proADM (midregional pro adrenomedullin), MR-proANP (midregional pro atrial natriuretic peptide), and CT-proET1 (C-terminal pro endothelin-1)) to aid in risk prediction and prognosis for heart failure. diaDexus will have exclusive rights to develop and commercialize diagnostic clinical laboratory tests based on these biomarkers in the United States.